You are here

Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Poway, California, 92064 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Colorectal Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or
rectum

- Stage IV or recurrent disease

- Measurable disease

- Disease progression or recurrence during or after completion of prior first-line
chemotherapy with fluorouracil and leucovorin calcium (5-FU/LV)

- Prior irinotecan or oxaliplatin as part of the 5-FU/LV regimen or as subsequent
therapy allowed

- Only 2 prior regimens for metastatic disease allowed

- One additional regimen as adjuvant therapy allowed provided patient remained
disease-free for > 6 months after completion of therapy*

- Newer, targeted investigational agents (e.g., cetuximab or bevacizumab) are not

counted as a chemotherapeutic regimen unless used in combination with a cytotoxic regimen
NOTE: *If evidence of failure occurred within therapy, patients may have received only 1 additional regimen for metastatic disease

- No active brain metastases (requiring treatment or progressing)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of blood transfusion within 14 days

- Need of concurrent Administration of allopurinol

- History of Radiotherapy or Chemotherapy within 4 weeks

- Any psychological or sociological condition, addidtive disorder or family problems
that might preclude compliance with the protocol

- Any unstable or severe intercurrent medical condition that in the opinion of th
einvestigator might interfere with achievement of study objectives

- Receipt of an investigational agent within 28 days prior to first day of dosing with
AG-2037

- Pregnant or breast feeding

- Previous treatment with GARFT inhibitors

- History of a malignancy (other than colorectal cancer) excpet those treated with
curative intent for skin cancer (other than melanoma) or in situ breast or cervical
cancer or those treated with curative intent for any other cancer with no evidence of
disease for 5 years

- Active brain metastases (requiring treatment or progression)

NCT00078468
Pfizer
Completed
Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now